Briefing
Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA.
Median 6 mutations per patient; PLEKHS1 promoter mutations in 46%.
- Design: Pretreatment or surveillance, early-stage BLCA
- n: 67 healthy adults and 118 patients with early-stage bladder cancer
- Assay: uCAPP-Seq (utDNA CAPP-Seq), targeted high-throughput sequencing